The LALF32-51 peptide as component of HPV therapeutic vaccine circumvents the alum-mediated inhibition of IL-12 and promotes a Th1 response
Autor: | Alain B. Alfonso, Aileen Batte, Enma Brown, Yordanka Soria, Yayrí C. Prieto, Laura Varas, Maribel G. Vallespi, Miladys Limonta, Milaid Granadillo, Isis Torrens |
---|---|
Jazyk: | angličtina |
Předmět: |
0301 basic medicine
Alum medicine.medical_treatment LALF32-51-E7 Biology Fusion protein 03 medical and health sciences chemistry.chemical_compound 030104 developmental biology 0302 clinical medicine Antigen chemistry Low Grade Squamous Intraepithelial Neoplasia Immunity 030220 oncology & carcinogenesis Humoral immunity Immunology Interleukin 12 medicine Immunology and Allergy Al(OH)3 Adjuvant |
Zdroj: | Journal of Cellular Immunotherapy. (1):44-51 |
ISSN: | 2352-1775 |
DOI: | 10.1016/j.jocit.2015.01.001 |
Popis: | Aluminum-containing adjuvants (alum) continue to be the most widely used adjuvants. It is common knowledge that these adjuvants predominantly induce humoral immunity, but some reports also describe their role combined with IL-12 in the induction of a Th1 immune response. In this study we want to investigate if alum could be an adjuvant to be used as a component of a therapeutic vaccine that require the generation of cell-mediated immunity. To demonstrate this concept we selected the human papillomavirus (HPV) 16-transformed mouse TC-1 cells as model and the fusion protein LALF32-51-E7 as antigen. Our results suggest that LALF32-51-E7 combined with aluminum hydroxide adjuvant promotes a Th1 immune response and consequently an anti-tumor response in the TC-1 tumor model. These results could have important application in future clinical trials in women with low grade squamous intraepithelial neoplasia. |
Databáze: | OpenAIRE |
Externí odkaz: |